<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2143">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05133258</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY02001093</org_study_id>
    <nct_id>NCT05133258</nct_id>
  </id_info>
  <brief_title>Antibiotic Concentration After Delivery to Middle Ear for Chronic Suppurative Otitis Media</brief_title>
  <official_title>Measuring Antibiotic Solution Concentration at the Tympanic Membrane Following Self-administration by Patients With Chronic Suppurative Otitis Media</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dartmouth-Hitchcock Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dartmouth-Hitchcock Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study team aims to elucidate the potential role of ototopical antibiotic concentration on&#xD;
      outcomes in patients diagnosed with chronic suppurative otitis media (CSOM). Chronic&#xD;
      suppurative otitis media (CSOM) is characterized by chronic inflammation of the middle ear&#xD;
      with persistent discharge from a non-intact tympanic membrane. CSOM is notably associated&#xD;
      with a significant burden of disease worldwide. Topical fluoroquinolones are first line&#xD;
      therapy for CSOM and are advantageous as compared to oral or intravenous therapy in that&#xD;
      these antibiotics avoid systemic side effects and have the potential to locally deliver high&#xD;
      antibiotic concentrations, which were thought to be sufficient to overcome all bactericidal&#xD;
      resistance to fluoroquinolones.&#xD;
&#xD;
      The investigators will measure antibiotic concentration in aspirates via liquid&#xD;
      chromatography with tandem mass spectrometry (LC-MS/MS) from the middle ear of selected&#xD;
      subjects with CSOM who are prescribed and instructed to self-administer ototopical&#xD;
      ciprofloxacin. Enrolled subjects will be asked to return 3 to 10 days after initial visit to&#xD;
      aspirate the middle ear and receive a follow-up evaluation. Furthermore, the subjects will be&#xD;
      asked to keep logs of their medication use and to administer the ototopical medication one&#xD;
      hour prior to their appointments. The measured ciprofloxacin concentrations will be&#xD;
      correlated with clinical outcomes, primarily the time to symptom resolution. The guiding&#xD;
      hypothesis is that patient self-administration of ciprofloxacin drops vary in antibiotic&#xD;
      delivery with diluted concentrations significantly below the in vitro concentration of the&#xD;
      prescribed solution and that these concentrations are below the bactericidal concentration of&#xD;
      ciprofloxacin-resistant bacteria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">April 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentration of Ciprofloxacin</measure>
    <time_frame>3 to 10 days after initial visit</time_frame>
    <description>Antibiotic Delivery to the Middle Ear will be measured by Ciprofloxacin concentration Relevant concentration range is 2000 ng/mL to 2,000,000 ng/mL, which are the minimum inhibitory concentration and theoretical maximum concentration, respectively. Measured through LC-MS/MS, aspirate collected 3-10 days after initial visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Compliance to Treatment as measured by Daily Compliance + Symptom Log</measure>
    <time_frame>Starting after the initial visit, for 10 days</time_frame>
    <description>The patient is given a medication and symptoms log to track administration of ototopical ciprofloxacin treatment (3 times per day for 10 days).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of Symptoms as measured by Daily Compliance + Symptom Log</measure>
    <time_frame>Starting after the initial visit, for 10 days. Afterwards, weekly surveys to monitor symptoms for a maximum followup of 12 weeks.</time_frame>
    <description>The patient is given a medication and symptoms log to track status of symptoms, which include ear discomfort, ear discharge, ear fullness, hearing changes, and &quot;other.&quot;</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Chronic Suppurative Otitis Media</condition>
  <arm_group>
    <arm_group_label>Chronic Suppurative Otitis Media group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Enrolled subjects with persistent otorrhea due to CSOM and prescribed with standard of care (prescription for antibiotic drops from a pharmacy of their choice with specific written instructions for self-administration).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ciprofloxacin and dexamethasone suspension</intervention_name>
    <description>ciprofloxacin 0.3% and dexamethasone 0.1% suspension</description>
    <arm_group_label>Chronic Suppurative Otitis Media group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients greater than or equal to 18 years of age&#xD;
&#xD;
          -  Diagnosis of Chronic Suppurative Otitis Media (CSOM)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atypical presentation of CSOM or atypical anatomy of the ear&#xD;
&#xD;
          -  Presence of additional ear pathophysiology beyond CSOM&#xD;
&#xD;
          -  Adults unable to consent&#xD;
&#xD;
          -  Individuals who are not yet adults (infants, children, teenagers)&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Prisoners&#xD;
&#xD;
          -  Non-English speaking&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>James Saunders, MD</last_name>
    <phone>6036508123</phone>
    <email>James.E.Saunders@hitchcock.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrew Y Lee, BS</last_name>
    <phone>2067907103</phone>
    <email>andrew.y.lee.med@dartmouth.edu</email>
  </overall_contact_backup>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>November 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 24, 2021</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dartmouth-Hitchcock Medical Center</investigator_affiliation>
    <investigator_full_name>James E. Saunders</investigator_full_name>
    <investigator_title>Professor of Otology / Neurotology</investigator_title>
  </responsible_party>
  <keyword>csom</keyword>
  <keyword>antibiotic resistance</keyword>
  <keyword>chronic suppurative otitis media</keyword>
  <keyword>ototopical ciprofloxacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suppuration</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Otitis Media, Suppurative</mesh_term>
    <mesh_term>Otitis</mesh_term>
    <mesh_term>Otitis Media</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciprofloxacin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 14, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT05133258/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 13, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT05133258/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

